NCT05172700 2024-12-18Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerEli Lilly and CompanyApproved for marketing
NCT04155190 2023-05-31An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCCSol-Gel Technologies, Ltd.Phase 2 Terminated47 enrolled